MMP-7 Modulation by Short and Long Term Radiotherapy in Rectal Cancer Patients

To analyse the effects of radiation therapy on inflammation and matrilysin levels in rectal cancer patients.

Completed

Looking for future studies?

Key information

Conditions

Rectal Cancer Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms Neoplasms Neoplasms by Site Rectal Diseases Rectal Neoplasms

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adenocarcinoma of the rectum, ability to understand written and oral information, written consent.

Exclusion criteria

Colon cancer, benign tumors, impaired general condition of patient, declining to participate in the study, synchronous colonic tumors, logistical reasons, inability to understand written and/or oral information, previous pelvic irradiation, ongoing immunosuppressive therapy, diabetes with systemic complications.

Treatment and study plan

Neoadjuvant radiotherapy

Radiation

Neoadjuvant radiotherapy prior to rectal cancer surgery

Primary outcomes

Matrilysin levels

Time frame: 1 - 6 weeks

Inflammatory markers

Sponsors and collaborators

Lead sponsor

Region Skane

Other

Registry information

Official study title

Effect of Long and Short Radiotherapy on MMP-7 Levels in Rectal Cancer Treatment

Acronym: MMP-7

Important dates

Study start: 2002
Primary completion: 2007
Study completion: 2007
First posted: May 12, 2017
Registry last updated: May 12, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed